Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML
Abstract: Despite the use of FMS-like tyrosine kinase 3 (FLT3) inhibitors, outcomes for patients with FLT3-mutated (FLT3mut) acute myeloid leukemia (AML) remain suboptimal because of high rates of relapse. We evaluated the safety and efficacy of the combination of daunorubicin, cytarabine (DA), gemt...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Elsevier
2025-12-01
|
| Seri Bilgileri: | Blood Advances |
| Online Erişim: | http://www.sciencedirect.com/science/article/pii/S2473952925005956 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|
